XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes true human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Metrics to compare | XBIT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipXBITPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.3x | −3.1x | −0.5x | |
PEG Ratio | 0.08 | −0.01 | 0.00 | |
Price/Book | 0.5x | 2.2x | 2.6x | |
Price / LTM Sales | - | 9.5x | 3.3x | |
Upside (Analyst Target) | - | 196.4% | 43.4% | |
Fair Value Upside | Unlock | 4.1% | 7.1% | Unlock |